255 related articles for article (PubMed ID: 26235259)
1. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Casanova C; Verlicchi A; Mazza V; Dazzi C
Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
[TBL] [Abstract][Full Text] [Related]
2. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
Falco I; Stragliotto S
Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
[TBL] [Abstract][Full Text] [Related]
3. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
4. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
[TBL] [Abstract][Full Text] [Related]
5. Long response to eribulin in breast cancer: a case report.
Borgonovo K; Petrelli F; Cabiddu M; Ghilardi M; Coinu A; Seghezzi S; Barni S
Future Oncol; 2015; 11(15 Suppl):3-8. PubMed ID: 26235258
[TBL] [Abstract][Full Text] [Related]
6. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient.
Scavelli C; Gallù F
Future Oncol; 2014 Nov; 10(14):2127-32. PubMed ID: 25471027
[TBL] [Abstract][Full Text] [Related]
9. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
Caputo R; Cianniello D; De Laurentiis M
Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
13. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
15. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
16. Eribulin long-term response and rechallenge: report of two clinical cases.
Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Bischoff J; Barinoff J; Mundhenke C; Bauerschlag DO; Costa SD; Herr D; Lübbe K; Marmé F; Maass N; von Minckwitz G; Grischke EM; Müller V; Schmidt M; Gerber B; Kümmel S; Schumacher C; Krabisch P; Seiler S; Thill M; Nekljudova V; Loibl S
Anticancer Drugs; 2019 Apr; 30(4):394-401. PubMed ID: 30875348
[TBL] [Abstract][Full Text] [Related]
18. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Lutrino ES; Orlando L; Febbraro A; Giampaglia M; Zamagni C; Schiavone P; Scavelli C; Dima G; Fedele P; Giordano G; Bilancia D; Quaranta AM; Rubino D; Filippelli G; Fontanella C; Caliolo C; Marino A; Calvani N; Ferrara P; Cinieri S
Tumori; 2020 Aug; 106(4):301-305. PubMed ID: 31847742
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.
Iorfida M; Mazza M
Future Oncol; 2015; 11(15 Suppl):23-6. PubMed ID: 26235261
[TBL] [Abstract][Full Text] [Related]
20. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]